AC Immune

There is no proven pricing power yet because no product is on the market. If successful, an Alzheimer’s or Parkinson’s active vaccine could command premium pricing versus standard vaccines but likely below the list prices of monoclonal antibodies such as donanemab and lecanemab, which run in the tens of thousands of dollars annually.

Any realized pricing power will hinge on demonstrable disease‑modifying efficacy, ARIA/safety profile advantages, and payer acceptance relative to anti‑amyloid antibodies that are already covered by Medicare. At this stage, latent pricing power exists in theory but cannot be relied upon.